At a glance
ClinicalIndex Comparison RecordN/ACompleted· 74 enrolled
Drug / intervention
Capecitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study of the Effect of Adjuvant Treatment With Capecitabine in Combination With Oxaliplatin on Disease-Free Survival in Patients With Stage III Colon Cancer
In Brief
An observational study evaluating Capecitabine and Oxaliplatin for Colorectal Cancer. Completed, enrolled 74 participants across 9 sites.
Detailed Summary
This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer. Data were collected from each participant for up to 36 months or until disease recurrence.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesSlovakia
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartOct 2011
Primary CompletionApr 2015
TodayJul 2026
First PostedSep 28, 2011
Enrollment StartOct 1, 2011
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 14.8 years ago
Interventions
Capecitabinedrug
Administered according to the Summary of Product Characteristics.
Oxaliplatinbiological
Administered according to the Summary of Product Characteristics.